Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 1 Mar 2007 |
| Orion Group Financial Review (proforma) 1-12/2006 | 6 Feb 2007 |
| Bulletin of Orion Corporation Financial Statements for 1 July 31 December 2006 | 6 Feb 2007 |
| Orion updates progress with Simdax (i.v. levosimendan) | 6 Feb 2007 |
| Matters to be handled at Orions AGM on 2 April 2007 | 6 Feb 2007 |